Type of lung cancer-Non-small cell lung carcinoma (NSCLC) - Page 2 of 14 Posts on Medivizor
Navigation Menu

Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor

Does anti-cancer therapy improve the outcomes of older patients with metastatic non-small cell lung cancer?

Does anti-cancer therapy improve the outcomes of older patients with metastatic non-small cell lung cancer?

Posted by on Feb 21, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at whether anti-cancer treatments can improve the outcomes of older patients with metastatic (cancer that has spread to a new location) non-small cell lung cancer (mNSCLC). The authors found that outcomes were improved with anti-cancer therapies in these patients. Some background NSCLC is responsible...

Read More

Searching for patients to trial an experimental medication for advanced solid tumors.

Searching for patients to trial an experimental medication for advanced solid tumors.

Posted by on Jan 28, 2021 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including lung cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out in...

Read More

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Posted by on Jan 19, 2021 in Lung cancer | 0 comments

In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP.  Some...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Melanoma | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some background...

Read More

Can erlotinib be used at a reduced dose to treat EGFR-mutated advanced non-small cell cancer?

Can erlotinib be used at a reduced dose to treat EGFR-mutated advanced non-small cell cancer?

Posted by on Dec 28, 2020 in Lung cancer | 0 comments

In a nutshell This study was carried out to look at the use of a reduced dose of erlotinib (Tarceva) in the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). The authors found that lower-dose erlotinib was as effective as standard dose gefitinib (Iressa) in these patients. Some background NSCLC is the...

Read More

Does chemoimmunotherapy have additional survival benefits compared to immunotherapy alone in the treatment of advanced non-small cell lung cancer?

Does chemoimmunotherapy have additional survival benefits compared to immunotherapy alone in the treatment of advanced non-small cell lung cancer?

Posted by on Dec 20, 2020 in Lung cancer | 0 comments

In a nutshell This study was carried out to compare the effectiveness of chemoimmunotherapy (CIT) to immunotherapy (IT) alone for advanced non-small cell lung cancer (NSCLC). The authors found that there was no significant benefit in overall survival with CIT over IT. Some background NSCLC is the most common form of lung cancer. NSCLC is responsible...

Read More

Searching for patients with non-small cell lung cancer to trial an immune treatment

Searching for patients with non-small cell lung cancer to trial an immune treatment

Posted by on Nov 22, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to examine the effectiveness of a new immune therapy, zimberelimab, alone or in combination with other immune therapies (domvanalimab and etrumadenant) in patients with PD-L1 positive non-small cell lung cancer (NSCLC). The main outcomes to be measured in this trial is the response rate and survival...

Read More

Evaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.

Evaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.

Posted by on Oct 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...

Read More

Is gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?

Is gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?

Posted by on Sep 8, 2020 in Lung cancer | 0 comments

In a nutshell This article looked at the effectiveness of gefitinib (Iressa) combined with chemotherapy when compared to a chemotherapy aline in the treatment of non-small cell lung cancer (NSCLC). The authors found that the addition of gefitinib to a chemotherapy increased the progression-free survival (PFS) of these...

Read More

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Posted by on Sep 6, 2020 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....

Read More